The HS monitor is part of Ipsos’ Autoimmune Real World Evidence portfolio. It launched in the EU5 in the second quarter of 2017, with plans to extend to other markets. 

The new syndicated study will combine real world evidence on the treatment of HS patients with treating doctors’ perceptions, providing an understanding of the HS landscape in the EU5. 

Subscribers to the monitor will be able to examine and size the HS market in each country (including the biologic market), understand HS patient journeys, gauge doctors’ perceptions of products used to treat HS and assess treatment approaches, among other information. 

“New biological treatments – together with their biosimilar counterparts – are transforming the autoimmune market, offering greater treatment options for patients and disrupting the traditional treatment paradigm," said Paul O'Meara, senior vice-president of autoimmune therapy monitors at Ipsos Healthcare.

"The ongoing expansion of Ipsos’ Autoimmune Therapy Monitor portfolio to include Hidradenitis Suppurativa will enable our clients, both local and global, to keep track of these therapeutic areas during this exciting time.”